How High Will Airbnb Stock Go?
Airbnb, Inc. (NASDAQ:ABNB) share price has seen substantial turbulence over…
Sell
46
BCPC Quote, Financials, Valuation and Earnings
Last price:
$167.06
Seasonality move
:
8.27%
Day range:
$164.84 - $167.20
52-week range:
$135.84 - $186.03
Dividend yield:
0.52%
P/E ratio:
44.88x
P/S ratio:
5.78x
P/B ratio:
4.61x
Volume:
55.6K
Avg. volume:
128.2K
1-year change:
12.62%
Market cap:
$5.4B
Revenue:
$922.4M
EPS (TTM):
$3.72
Analysts' Opinion
-
Consensus RatingBalchem has received a consensus rating of --. The company's average rating is a -- based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Balchem has an estimated upside of 14% from its current price of $166.96.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $166.96.
Fair Value
-
According to the consensus of 0 analysts, Balchem has 14% upside to fair value with a price target of -- per share.
BCPC vs. S&P 500
-
Over the past 5 trading days, Balchem has underperformed the S&P 500 by -1% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Balchem does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Balchem has grown year-over-year revenues for 3 quarters straight. In the most recent quarter Balchem reported revenues of $239.9M.
Earnings Growth
-
Balchem has grown year-over-year earnings for 6 quarters straight. In the most recent quarter Balchem reported earnings per share of $1.03.
Enterprise value:
5.6B
EV / Invested capital:
3.97x
Price / LTM sales:
5.78x
EV / EBIT:
32.03x
EV / Revenue:
5.92x
PEG ratio (5yr expected):
2.70x
EV / Free cash flow:
34.36x
Price / Operating cash flow:
33.54x
Enterprise value / EBITDA:
24.76x
Gross Profit (TTM):
$324.9M
Return On Assets:
7.63%
Net Income Margin (TTM):
12.9%
Return On Equity:
11.16%
Return On Invested Capital:
8.77%
Operating Margin:
20%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $923M | $926.3M | $942.4M | $229.9M | $239.9M | |
| Gross Profit | $275.9M | $295.7M | $324.9M | $76.5M | $85.4M | |
| Operating Income | $145.7M | $154.2M | $173.8M | $43.6M | $48M | |
| EBITDA | $197M | $207M | $225.4M | $56.9M | $58.9M | |
| Diluted EPS | $3.35 | $3.19 | $3.72 | $0.90 | $1.03 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $270.1M | $300.3M | $368.1M | $341.2M | $326M | |
| Total Assets | $1.2B | $1.2B | $1.6B | $1.6B | $1.6B | |
| Current Liabilities | $68.4M | $104.9M | $142.1M | $108M | $109.4M | |
| Total Liabilities | $341.9M | $290.3M | $737.1M | $578.2M | $419.7M | |
| Total Equity | $819.4M | $889.1M | $895.9M | $1B | $1.2B | |
| Total Debt | $193.6M | $108.6M | $462.6M | $380.6M | $227M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $141.4M | $158M | $197.1M | $46.5M | $51.3M | |
| Cash From Investing | -$415.7M | -$37.4M | -$34.6M | -$9.3M | -$9.2M | |
| Cash From Financing | $252.1M | -$104.6M | -$168.7M | -$25.1M | -$34.4M | |
| Free Cash Flow | $90.6M | $117.7M | $162.4M | $38.2M | $42.2M | |
BCPC
Sector
Market Cap
$5.4B
$18.9M
Price % of 52-Week High
89.75%
57.66%
Dividend Yield
0.52%
0%
Shareholder Yield
1.18%
1.61%
1-Year Price Total Return
12.62%
-18.53%
Beta (5-Year)
0.668
1.064
Dividend yield:
0.52%
Annualized payout:
$0.79
Payout ratio:
21.04%
Growth streak:
14 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$168.33
200-day SMA
Buy
Level
$164.23
Bollinger Bands (100)
Sell
Level
167.46 - 177.64
Chaikin Money Flow
Buy
Level
28.4M
20-day SMA
Sell
Level
$174.10
Relative Strength Index (RSI14)
Sell
Level
35.52
ADX Line
Sell
Level
12.58
Williams %R
Buy
Level
-80.3048
50-day SMA
Sell
Level
$174.51
MACD (12, 26)
Sell
Level
-2.86
25-day Aroon Oscillator
Sell
Level
-76
On Balance Volume
Neutral
Level
28M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (7.1184)
Buy
CA Score
(Annual)
Level (0.7504)
Buy
Beneish M-Score
(Annual)
Level (-2.7397)
Buy
Momentum Score
Level (9)
Buy
Ohlson Score
Level (-1.4167)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (10)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Balchem Corp is engaged in the development, manufacture, and marketing of specialty performance ingredients and products for the food, nutritional, feed, pharmaceutical, agricultural, and medical sterilization industries. The segments include 1) Human Nutrition and Health segment provides human-grade choline nutrients and mineral amino acid chelated products through this segment for nutrition and health applications. 2) The Animal Nutrition and Health segment provide nutritional products derived from its microencapsulation and chelation technologies in addition to the essential nutrient choline chloride. 3) The Specialty Products segment includes re-packaging and distributing a number of performance gases and chemicals for various uses, notably ethylene oxide, propylene oxide, and ammonia.
Stock Forecast FAQ
In the current month, BCPC has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The BCPC average analyst price target in the past 3 months is --.
-
Where Will Balchem Stock Be In 1 Year?
According to analysts, the consensus estimate is that Balchem share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Balchem?
Analysts are divided on their view about Balchem share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Balchem is a Sell and believe this share price will drop from its current level to --.
-
What Is Balchem's Price Target?
The price target for Balchem over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is BCPC A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Balchem is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of BCPC?
You can purchase shares of Balchem via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Balchem shares.
-
What Is The Balchem Share Price Today?
Balchem was last trading at $167.06 per share. This represents the most recent stock quote for Balchem. Yesterday, Balchem closed at $166.96 per share.
-
How To Buy Balchem Stock Online?
In order to purchase Balchem stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is SoundHound AI Stock Up So Much?
Like many companies improving AI technologies and exploring ways to…
Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 43x
Buy
56
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
57
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
64
ARQQ alert for Dec 27
Arqit Quantum [ARQQ] is up 49.85% over the past day.
Buy
64
QMCO alert for Dec 27
Quantum [QMCO] is up 49.62% over the past day.
Buy
65
ALGS alert for Dec 27
Aligos Therapeutics [ALGS] is up 10.88% over the past day.
